All glucose-lowering drugs for T2DM can beneficially impact on some of the mechanisms possibly involved in sarcopenia; in fact, they improve blood glucose control and insulin sensitivity, inhibit AGEs formation, and improve inflammation and the oxidative stress. The gene discussed is INS; the disease is sarcopenia.